Compare EHAB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHAB | KROS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 10800 | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.9M | 584.9M |
| IPO Year | 2020 | 2020 |
| Metric | EHAB | KROS |
|---|---|---|
| Price | $13.62 | $10.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $13.84 | ★ $22.25 |
| AVG Volume (30 Days) | ★ 2.3M | 415.8K |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 97.11 | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | ★ $1,060,000,000.00 | $243,864,000.00 |
| Revenue This Year | $6.42 | N/A |
| Revenue Next Year | $4.88 | $727.07 |
| P/E Ratio | ★ N/A | $4.83 |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $6.47 | $9.12 |
| 52 Week High | $13.66 | $22.55 |
| Indicator | EHAB | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 78.33 | 22.11 |
| Support Level | $10.79 | $10.49 |
| Resistance Level | $13.65 | $15.21 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 43.75 | 6.56 |
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.